Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck, Modifi
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Modifi on Wednesday said the deal gives Rahway, N.J., drugmaker Merck access to preclinical compounds designed to exploit DNA repair defects in hard-to-treat cancers, including glioblastoma, the most aggressive type of brain tumor.
Modifi Biosciences Acquired by Merck
In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founder,
1h
on MSN
CDC Panel Favors Wider Use of Pfizer, Merck Pneumococcal Shots
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
6h
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi has agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to ...
FiercePharma
55m
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
BioWorld
22h
Modifi acquired by Merck in $1.3B deal
Spun out of Yale University in 2021, it published data on DNA in Science in July 2022, and now it’s being acquired by
Merck
...
2d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...
7h
Merck & Company (MRK) Receives a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...
6d
Merck KGaA Trims Health Care And Life Sciences Targets, Eyes M&A
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...
5d
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
The Journal
22h
Merck Animal Health introduces SENSEHUB Dairy Youngstock
Merck
Animal Health, a division of
Merck
& Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the ...
1d
on MSN
How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute
"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Modifi Biosciences
New York Stock Exchange
RSV
MRK
clesrovimab
Feedback